MOLECULAR THERAPEUTICS PROGRAM The Molecular Therapeutics (MT) program is dedicated to evaluating cancer targets, developing novel therapies, and devising more effective delivery systems via highly integrated basic science and translational activities. The Program is led by Stephen Frye, Director of the Center for Integrative Chemical Biology and Drug Discovery (CICBDD) and Fred Eshelman Distinguished Professor, and Gary Johnson, Kenan Distinguished Professor in the Department of Pharmacology. The MT Program consists of 42 members who are associated with four schools and 16 departments. During the last funding period, program members have published 675 cancer-related articles. MT is highly collaborative. 16% of these papers are intra-programmatic and 33% are inter-programmatic (43% collaborative). In 2019, our program members held grants totaling $20.9M (direct cost) in cancer-relevant extramural funding, including $6.4M (direct costs) from the NCI and $13.0M other peer funding. The MT program is comprised of investigators with expertise in five broad areas: Chemical and Structural Biology; Drug Discovery and Development; Drug Delivery and Nanotechnology; Systems Pharmacology; and Oncogenic Signaling. Many investigators in the program have active collaborations with other LCCC programs, using and providing direction for LCCC's shared resources. These interactions enable many of the scientific steps needed for the discovery and development of promising therapies. In 2015, MT was rated ?outstanding? stating ?the minor weakness of this program is that, relatively few of the promising therapeutics have moved into investigator initiated clinical trials at the LCCC.? Since this review, multiple clinical studies have been initiated at UNC and other institutions based on discoveries in MT, as outlined in our response to the prior critique. Future plans build on unique translational resources available due to the creation of the Eshelman Institute for Innovation and Pinnacle Hill, which bring more than $100 million to progress UNC-based discoveries into patients. Cellular and biologic therapies will be an area of future focus for MT members enabled by the expansion of the Clinical Immunotherapy Program's GMP facility. Through these efforts, MT will continue to accelerate discovery of new cancer therapeutics and, with the Clinical Research and Breast Cancer Programs, design and execute translational and therapeutic trials in our patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089813
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Anderson, Chelsea; Smitherman, Andrew B; Nichols, Hazel B (2018) Conditional relative survival among long-term survivors of adolescent and young adult cancers. Cancer 124:3037-3043
Liu, Meng-Xi; Jin, Lei; Sun, Si-Jia et al. (2018) Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene 37:1637-1653
Curtis 2nd, Alan D; Jensen, Kara; Van Rompay, Koen K A et al. (2018) A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques. J Med Primatol 47:288-297
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Amunugama, Ravindra; Willcox, Smaranda; Wu, R Alex et al. (2018) Replication Fork Reversal during DNA Interstrand Crosslink Repair Requires CMG Unloading. Cell Rep 23:3419-3428
Little, Michael S; Pellock, Samuel J; Walton, William G et al. (2018) Structural basis for the regulation of ?-glucuronidase expression by human gut Enterobacteriaceae. Proc Natl Acad Sci U S A 115:E152-E161
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 556:135
Dellon, Evan S; Selitsky, Sara R; Genta, Robert M et al. (2018) Gene expression-phenotype associations in adults with eosinophilic esophagitis. Dig Liver Dis 50:804-811
Rojas, Juan D; Lin, Fanglue; Chiang, Yun-Chen et al. (2018) Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. Theranostics 8:141-155
Chai, Zheng; Zhang, Xintao; Rigsbee, Kelly Michelle et al. (2018) Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration. J Control Release 286:415-424

Showing the most recent 10 out of 1525 publications